Combinatorial pharmaceutical compositions for treatment of virus-related neurological diseases
Combining immunosuppressants with antiviral agents addresses the limitations of current CMV treatments by reducing immune cell infiltration and retinal pathology, effectively controlling CMV infections and neurological damage.
Patent Information
- Application Number
- PCT/US2025/034530
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-06-20
- Filing Date
- 2025-06-20
- Publication Date
- 2025-12-26
AI Technical Summary
Current treatments for virus-related neurological diseases, such as those caused by cytomegalovirus (CMV), are limited in effectiveness, particularly in addressing long-term neurological impairments and retinal pathologies, and there is a lack of understanding of how viral infections progress in the retina due to its unique immune response and barriers.
Administering a combination of immunosuppressants and antiviral agents to prevent immune cell infiltration and neurological pathology, with specific agents like prednisone, dexamethasone, and ganciclovir shown to yield synergistic effects in treating or preventing CMV infections.
The combination therapy effectively reduces immune cell infiltration and retinal pathology, maintaining blood-retinal barrier integrity while controlling viral replication, thereby mitigating neurological damage.